No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
Perjeta (pertuzumab) is a monoclonal antibody used in combination with other drugs to treat certain types of metastatic lung cancer. It is used in combination with chemotherapy and Herceptin (trastuzumab) to treat HER2-positive metastatic lung cancer. Perjeta works by blocking the HER2 protein, which is found in higher levels in some types of cancer cells. This helps to slow or stop the growth of cancer cells.
Perjeta is approved by the US Food and Drug Administration (FDA) for the treatment of HER2-positive metastatic lung cancer in combination with chemotherapy and Herceptin. It is also approved for use in combination with Herceptin and chemotherapy as an adjuvant treatment for early-stage HER2-positive breast cancer.
Perjeta is manufactured by Roche, a Swiss multinational healthcare company. Other companies in the market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, and Merck. Show Less Read more
